Literature DB >> 8187656

Response of falciparum malaria to chloroquine and three second line antimalarial drugs in a Kenyan coastal school age population.

B Hagos1, B Khan, A V Ofulla, D Kariuki, S K Martin.   

Abstract

Ambulatory rural school children in the Mombasa area with P. falciparum parasitaemia were examined and randomly assigned to treatment with one of three second-line antimalarials--amodiaquine, pyrimethamine/sulphadoxine (P/SD) and pyrimethamine/sulfalene (P/SL). Clinical signs and parasitaemia were followed daily for the first week and on days 14 and 28. WHO Mark II schizont inhibition tests were performed for all the above 3 drugs and chloroquine. The total number of cases was 73. The mean parasite density was 142.1 +/- 207; 102.7 +/- 166; 82.74 +/- 93 parasites per 300 WBC for amodiaquine, P/SD, and P/SL, respectively. In vitro tests showed a chloroquine resistance rate of 60% and no resistance to all of the second line drugs. Also, all children treated successfully cleared their parasitaemia with mean clearance rates of 2.05 +/- 0.57; 1.86 +/- 0.47; 2.05 +/- 0.50 days for amodiaquine, P/SD and P/SL, respectively. Even though, no difference in the effectiveness between the second line drugs used was found, reinfection rates as depicted by day 28 parasitaemia differed--amodiaquine 16%; P/SD 0%; and P/SL4.35%. This difference could be attributed to the difference in the pharmacokinetic properties of the drugs.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Age Factors; Child; Clinical Research; Comparative Studies; Demographic Factors; Developing Countries; Diseases; Drugs; Eastern Africa; English Speaking Africa; Kenya; Malaria; Parasitic Diseases; Population; Population Characteristics; Research Methodology; Research Report; School Age Population; Studies; Treatment; Youth

Mesh:

Substances:

Year:  1993        PMID: 8187656

Source DB:  PubMed          Journal:  East Afr Med J        ISSN: 0012-835X


  2 in total

1.  Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987--2006.

Authors:  Laura K Certain; Marnie Briceño; Steven M Kiara; Alexis M Nzila; William M Watkins; Carol Hopkins Sibley
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 5.226

2.  A fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan.

Authors:  Ishag Adam; Mamoun Magzoub; Maha E Osman; Insaf F Khalil; Michael Alifrangis; Khalid A Elmardi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-08-26       Impact factor: 3.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.